Korean J Clin Microbiol.  2009 Sep;12(3):122-128. 10.5145/KJCM.2009.12.3.122.

Evaluation of VITEK-2 Antifungal Susceptibility Test (AST-YS01) for Candida Species Isolates in Korea

• Kim DW
• Shin JH
• Kee SJ
• Kim SH
• Shin MG
• Suh SP
• Ryang DW

• KMID: 1828582
• DOI: http://doi.org/10.5145/KJCM.2009.12.3.122

Abstract

BACKGROUND
VITEK-2 yeast susceptibility test (AST- YS01; bioMerieux, Hazelwood, MO, USA) has recently been introduced as a fully automated commercial antifungal susceptibility test system that determines MIC (minimum inhibitory concentrations) endpoints spectrophotometrically, thereby eliminating subjective errors. We compared the VITEK-2 system with the CLSI (the Clinical and Laboratory Standards Institute) M27 method for susceptibility testing of Candida isolates from Korea.
METHODS
A total of 175 Candida bloodstream isolates were collected from two hospitals during a 18-month period. We compared the MIC results for amphotericin B, fluconazole and voriconazole obtained with the VITEK-2 system to those obtained by the CLSI M27 broth microdilution method after 24-hr and 48-hr incubation.
RESULTS
VITEK-2 system MIC endpoints for 175 isolates were determined after 11.75 to 35.50 hr of incubation (mean, 16.3+/-4.8 hr). The essential agreement (within 2 dilutions) between amphotericin B, fluconazole and voriconazole MICs obtained by the VITEK-2 system and CLSI method was 98.3%, 90.9% and 96.0%, respectively, at 24-hr incubation and 100%, 92.6% and 94.9%, at 48-hr incubation. The categorical discrepancy for fluconazole was 6.3% (major error, 2.9% and minor error, 3.4%) at 24-hr and 6.3% (major error, 2.3% and minor error, 4.0%) at 48-hr. The categorical discrepancy for voriconazole was 1.7% (major error, 1.1% and minor error, 0.6%) at both 24-hr and 48-hr. There were no very major errors for fluconazole and voriconazole.
CONCLUSION
The VITEK-2 antifungal susceptibility test system appears to be rapid and highly correlative with the CLSI method, sugesting that this system can be effective for antifungal susceptibility testing for Candida species in the clinical laboratory.

Keyword

Candida; VITEK-2; Antifungal susceptibility; CLSI

MeSH Terms

Amphotericin B
Candida
Fluconazole
Korea
Pyrimidines
Triazoles
Yeasts
Amphotericin B
Fluconazole
Pyrimidines
Triazoles

Reference

1. Shin JH. Antifungal drug susceptibility. Hanyang Med Rev. 2006; 26:79–85.

2. Clinicaland Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, Third ed., M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA. 2008.

3. Murray PR, Baron EJ, et al. eds. Manual of Clinical Microbiology. 9th ed.Washington DC: American Society for Microbiology;2007. p. 1972–86.

4. Pfaller MA, Yu WL. Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am. 2001; 15:1227–61.

5. Pfaller MA. Antifungal susceptibility testing methods. Current Drug Targets. 2005; 6:929–43.

6. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol. 2007; 45:796–802.

7. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol. 2007; 45:3522–8.

8. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J. 2007; 48:779–86.

9. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006; 44:819–26.

10. Park JY, Shin JH, Uh Y, Kim EC, Kee SJ, Kim SH, et al. In vitro amphotericin B susceptibility of Korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and minimum fungicidal concentration test. Korean J Lab Med. 2008; 28:346–52.

11. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003; 82:309–21.

12. Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. Food and Drug Administration, Rockville, MD. 2007.

13. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol. 2009; 47:296–304.